Postdoc-TherapeuticEpigeneticEditinginvivo

Your group Hackett Your supervisor Jamie Hackett Your role You will play a central role in a pioneering an _in vivo_ epigenome editing programme, deploying CRISPR-based epigenetic editors to modulate target gene expression in the liver. Based at EMBL and working in close collaboration with biotech partners, you will drive experimental progression from AAV/LNP-mediated delivery in mouse models, through rigorous genomics and biodistribution analyses, to metabolic and disease phenotyping. The goal is to engineer therapeutically relevant changes in hepatic gene expression, with direct application to disease. This means working at the frontier of epigenome editing in mouse models, where mechanistic insight meets translational impact. The role sits at an exciting academic–industry interface, giving you direct exposure to biotech operating models, clinically oriented experimental design, and milestone-driven programme management. While the work is structured and output-focused, there is genuine scope to contribute to scientific strategy and ownership of experimental direction alongside industry scientists. You will also have the possibilty to co-lead and mentor a small team of researchers - building real scientific leadership experience in a translational setting. This position is an opportunity for motivated scientists to build an academic or industry career in gene therapy and state-of-the-art CRISPR technologies, and drive bottom-up therapeutic development. You have * PhD in gene therapy, (epi)genomics, liver biology, or a closely related field * Hands-on _in vivo_ experience in rodent models, ideally including AAV and/or LNP delivery and tissue collection​ * Strong command of core molecular biology techniques (qRT-PCR, ChIP, cloning, histology) and experience with CRISPR design and implementation * Motivation to work in an international team bridging academia and biotech, driving technologies towards clinical translation * Good communication and interpersonal skills; f